STOCK TITAN

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Verastem Oncology (VSTM) to participate in fireside chat at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024
Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET.

To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.

Following the event, an archived replay of the fireside chat will be available on the investors section of the Company’s website at www.verastem.com.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Investors:

Ryan Porter

Argot Partners

+1 212-600-1902

ryan.porter@argotpartners.com

Media:

Lisa Buffington

Corporate Communications

+1 781-292-4502

lbuffington@verastem.com

Source: Verastem Oncology

Verastem Oncology (VSTM) will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET.

To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.

Following the event, an archived replay of the fireside chat will be available on the investors section of the Company’s website at www.verastem.com.
Verastem, Inc.

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Stock Data

243.71M
13.68M
0.55%
66.74%
2.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEEDHAM

About VSTM

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com